Requip (ropinirole) is the SECOND new drug for Parkinson's

November 1997

You now have a new option for treating Parkinson's.

Requip (ropinirole) is the SECOND new drug for Parkinson's to hit the market this year.

The first one, Mirapex (pramipexole), was approved in July.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Self-treatment for high cholesterol
new steroid nasal spray, Nasonex
metered-dose inhalers (MDIs) instead of a nebulizer to treat ACUTE asthma or COPD
Famvir and Valtrex are now approved for long-term therapy
AZT and 3TC COMBINED into one tablet called Combivir
Hepatitis C Infergen for chronic hepatitis C
Hepatitis C lamivudine (Epivir, 3TC) for chronic hepatitis B
Hypertension Avapro (irbesartan) for hypertension
which vit E supplements are best
Nascobal, a prescription vit B-as Nasal Gel
asking about alpha lipoic acid
Dermatology Soriatane (acitretin), a new oral retinoid
Neurology Pain Requip (ropinirole) is the SECOND new drug for Parkinson's
Neurology Pain epileptic patients will be put on Gabitril (tiagabine)
Alzheimer s Disease new JAMA study about using ginkgo for Alzheimer's
Antipsychotics Seroquel (quetiapine) just hit the market
The FDA will approve thalidomide
Practice JNC VI this month to guide hypertension treatment
Practice Arthrotec, a new combination of diclofenac (Voltaren) and misoprostol (Cytotec) for arthritis